Bauerlein’s appointment became effective on April 3. She joins from Inogen, having cofounded the medtech company in 2001 and served as CFO from 2009 through 2021. In that role, she oversaw the global finance and accounting functions, helping to scale Inogen from a startup to a company bringing in more than $350 million in annual sales.
She also served as a member of the board of directors at Pear Therapeutics, having joined in December 2021. She’s been a member of the board of directors at Gelesis since January 2022. Bauerlein serves as chair of the audit committees for both Pear and Gelesis. Additonally, she served as a member of Koya Medical since 2021.
“I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will provide an immediate and valuable impact,” said Paul Badawi, co-founder and CEO of Sight Sciences.
Sight Sciences develops ophthalmology and optometry devices. Its Omni surgical system delivers treats adult patients with open-angle glaucoma (OAG).
“Sight Sciences is a leader in eyecare technology innovation with a portfolio and pipeline of products disrupting two distinct multibillion-dollar markets and generating top-tier revenue growth,” Bauerlein said. “I have firsthand experience with this stage of transformational growth and development and am excited to leverage my background in high-growth medtech to help Sight Sciences achieve its fullest potential.”
